Works matching DE "NILOTINIB"

Results: 556

Clinical Trial Highlights – Kinase Inhibitors.

Published in:

Journal of Parkinson's Disease, 2021, v. 11, n. 2, p. 377, doi. 10.3233/JPD-219003

By:

Prakash, Neha;
McFarthing, Kevin;
Simuni, Tanya

Publication type:

Article

Clinical Trial Highlights: Targetting Alpha-Synuclein.

Published in:

Journal of Parkinson's Disease, 2019, v. 9, n. 1, p. 5, doi. 10.3233/JPD-189004

By:

McFarthing, Kevin;
Simuni, Tanya

Publication type:

Article

Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?

Published in:

2017

By:

Schwarzschild, Michael A.

Publication type:

Letter to the Editor

Nilotinib - Differentiating the Hope from the Hype.

Published in:

Journal of Parkinson's Disease, 2016, v. 6, n. 3, p. 519, doi. 10.3233/JPD-160904

By:

Wyse, Richard K.;
Brundin, Patrik;
Sherer, Todd B.

Publication type:

Article

Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies.

Published in:

Journal of Parkinson's Disease, 2016, v. 6, n. 3, p. 503, doi. 10.3233/JPD-160867

By:

Pagan, Fernando;
Hebron, Michaeline;
Valadez, Ellen H.;
Torres-Yaghi, Yasar;
Xu Huang;
Millsb, Reversa R.;
Wilmarth, Barbara M.;
Howard, Hellen;
Dunn, Connell;
Carlson, Alexis;
Lawler, Abigail;
Rogers, Sean L.;
Falconer, Ramsey A.;
Ahn, Jaeil;
Zhaoxia Li;
Moussa, Charbel

Publication type:

Article

Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review.

Published in:

Journal of Applied Hematology, 2025, v. 16, n. 2, p. 171, doi. 10.4103/joah.joah_53_25

By:

Grari, Oussama;
Khermach, Assya;
Chahid, Nouhaila;
Douzi, Nisma;
Himri, Amina;
Berhili, Abdelilah;
Slaoui, Mounia;
Trougouty, Nabiha;
Bensalah, Mohammed;
Seddik, Rachid

Publication type:

Article

Nose to brain delivery of nanostructured lipid carriers loaded with rivastigmine and nilotinib for treating Alzheimer's disease: preparation, cell line study, and in vivo evaluation.

Published in:

Discover Nano, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s11671-025-04276-w

By:

Khan, Saif Ahmad;
Qamar, Zufika;
Kamboj, Sunil;
Moonis, Mohammad;
Rai, Garima;
Dang, Shweta;
Singh, Pirthi Pal;
Alam, Ozair;
Parvez, Suhel;
Baboota, Sanjula;
Ali, Javed

Publication type:

Article

Cardiovascular Toxicity of Biologic Agents for Cancer Therapy.

Published in:

Oncology (08909091), 2014, v. 28, n. 6, p. 482

By:

BHAVE, MANALI;
AKHTER, NAUSHEEN;
ROSEN, STEVEN T.

Publication type:

Article

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.

Published in:

European Journal of Clinical Pharmacology, 2020, v. 76, n. 9, p. 1213, doi. 10.1007/s00228-020-02910-3

By:

Boons, Christel C. L. M.;
Timmers, Lonneke;
Janssen, Jeroen J. W. M.;
Westerweel, Peter E.;
Blijlevens, Nicole M. A.;
Smit, Willem M.;
Bartelink, Imke H.;
Wilschut, Janneke A.;
Swart, Eleonora L.;
Hendrikse, N. Harry;
Hugtenburg, Jacqueline G.

Publication type:

Article

Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling.

Published in:

European Journal of Clinical Pharmacology, 2019, v. 75, n. 6, p. 825, doi. 10.1007/s00228-019-02640-1

By:

Boons, Christel C. L. M.;
Timmers, Lonneke;
Janssen, Jeroen J. W. M.;
Swart, Eleonora L.;
Hugtenburg, Jacqueline G.;
Hendrikse, N. Harry

Publication type:

Article

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, n. 4, p. 813, doi. 10.1007/s00228-012-1385-4

By:

Giles, Francis;
Yin, Ophelia;
Sallas, William;
Coutre, Philipp;
Woodman, Richard;
Ottmann, Oliver;
Baccarani, Michele;
Kantarjian, Hagop

Publication type:

Article

Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.

Published in:

Amino Acids, 2020, v. 52, n. 4, p. 511, doi. 10.1007/s00726-020-02832-5

By:

Yang, Yuping;
Qiu, Yue;
Liu, Xu;
Liu, Yanhua;
Yin, Yaling;
Li, Peng

Publication type:

Article

Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01080-3

By:

Bai, Jun;
Feng, Zuxi;
Chen, Yaqiong;
Li, Yanhong;
Zhang, Liansheng;
Li, Lijuan

Publication type:

Article

Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.

Published in:

Journal of Liposome Research, 2022, v. 32, n. 4, p. 386, doi. 10.1080/08982104.2022.2040532

By:

Pardeshi, Snehal;
Tiwari, Amrendra;
Titame, Uday;
Singh, Pankaj K;
Yadav, Pavan Kumar;
Chourasia, Manish K.

Publication type:

Article

Clinical significance of serum prohibitin in chronic myeloid leukemia patients on first-line tyrosine kinase inhibitors.

Published in:

Egyptian Journal of Haematology, 2023, v. 48, n. 1, p. 55, doi. 10.4103/ejh.ejh_57_21

By:

Yassin, Heba A.;
Azaazi, Mohamed O.;
Hegab, Hany M.;
Nabih, Nermine A.;
Rakha, Nahed M.;
Naguib, Mary G.

Publication type:

Article

Tyrosine kinase inhibitors reduce myeloid-derived suppressor cells in patients with chronic myeloid leukemia with better outcome.

Published in:

Egyptian Journal of Haematology, 2022, v. 47, n. 4, p. 272, doi. 10.4103/ejh.ejh_37_22

By:

Refaat, Youmna;
Rahman, Youseria;
Mohammed Saleh, Mostafa;
Sayed, Douaa;
Elzohri, Mona

Publication type:

Article

The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2021, v. 128, n. 4, p. 621, doi. 10.1111/bcpt.13537

By:

Cagno, Valeria;
Magliocco, Gaelle;
Tapparel, Caroline;
Daali, Youssef

Publication type:

Article

Nilotinib Interferes with the Signalling Pathways Implicated in Acetaminophen Hepatotoxicity.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2014, v. 114, n. 3, p. 263, doi. 10.1111/bcpt.12144

By:

Shaker, Mohamed E.

Publication type:

Article

Chemical Modification of Curcumin into Its Semi-Synthetic Analogs Bearing Pyrimidinone Moiety as Anticancer Agents.

Published in:

Plants (2223-7747), 2022, v. 11, n. 20, p. 2737, doi. 10.3390/plants11202737

By:

Afzal, Obaid;
Yusuf, Mohammad;
Ahsan, Mohamed Jawed;
Altamimi, Abdulmalik S. A.;
Bakht, Md. Afroz;
Ali, Amena;
Salahuddin

Publication type:

Article

DDR1 inhibition as a new therapeutic strategy for colorectal cancer.

Published in:

Molecular & Cellular Oncology, 2018, v. 5, n. 4, p. 1, doi. 10.1080/23723556.2018.1465882

By:

Sirvent, Audrey;
Lafitte, Marie;
Roche, Serge

Publication type:

Article

Impact of Treatment with Imatinib on Renal Histology in Albino Rats.

Published in:

Jordan Medical Journal, 2020, v. 54, n. 3, p. 99

By:

Al-Allaf, Luma Ibrahim Khalel;
Al-Ashoo, Hafidh

Publication type:

Article

BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia.

Published in:

Oncology Letters, 2024, v. 28, n. 3, p. N.PAG, doi. 10.3892/ol.2024.14557

By:

Schmidlechner, Lena;
Nagel, Inga;
Vater, Inga;
Cascorbi, Ingolf;
Kaehler, Meike

Publication type:

Article

Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Published in:

Oncology Letters, 2019, v. 18, n. 2, p. 2102, doi. 10.3892/ol.2019.10518

By:

Kroschwald, Lysann Michaela;
Tauer, Josephine Tabea;
Kroschwald, Sonja Ingrid;
Suttorp, Meinolf;
Wiedenfeld, Anne;
Beissert, Stefan;
Bauer, Andrea;
Rauner, Martina

Publication type:

Article

Therapeutic immune monitoring of CD4<sup>+</sup>CD25<sup>+</sup> T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Published in:

Oncology Letters, 2017, v. 14, n. 2, p. 1363, doi. 10.3892/ol.2017.6294

By:

ZIYUAN LU;
NA XU;
XUAN ZHOU;
GUANLUN GAO;
LIN LI;
JIXIAN HUANG;
YULING LI;
QISI LU;
BOLIN HE;
CHENGYUN PAN;
XIAOLI LIU

Publication type:

Article

Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.

Published in:

Oncology Letters, 2017, v. 13, n. 5, p. 3269, doi. 10.3892/ol.2017.5844

By:

KRAMER, BENEDIKT;
SCHULTZ, JOHANNES DAVID;
HOCK, CLEMENS;
SAUTER, ALEXANDER;
STUCK, BORIS A.;
HÖRMANN, KARL;
BIRK, RICHARD;
ADERHOLD, CHRISTOPH

Publication type:

Article

Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: A case report.

Published in:

Molecular & Clinical Oncology, 2019, v. 10, n. 2, p. 239

By:

Suzuki, Kohei;
Yamamoto, Junkoh;
Kakeda, Shingo;
Takamatsu, Seishiro;
Miyaoka, Ryo;
Kitagawa, Takehiro;
Saito, Takeshi;
Nakano, Yoshiteru;
Nishizawa, Shigeru

Publication type:

Article

A DNA Biosensor Based on a Raspberry‐like Hierarchical Nano‐structure for the Determination of the Anticancer Drug Nilotinib.

Published in:

ChemistryOpen, 2022, v. 11, n. 3, p. 1, doi. 10.1002/open.202100261

By:

Moarefdoust, Mohammad Mehdi;
Jahani, Shohreh;
Moradalizadeh, Mehran;
Motaghi, Mohammad Mehdi;
Foroughi, Mohammad Mehdi

Publication type:

Article

Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.

Published in:

Frontiers in Psychology, 2019, p. N.PAG, doi. 10.3389/fpsyg.2019.00329

By:

Borghi, Lidia;
Galimberti, Sara;
Baratè, Claudia;
Bonifacio, Massimiliano;
Capochiani, Enrico;
Cuneo, Antonio;
Falzetti, Franca;
Iurlo, Alessandra;
Lunghi, Francesca;
Minotto, Claudia;
Orlandi, Ester Maria;
Rege-Cambrin, Giovanna;
Sica, Simona;
Supekar, Sharon;
Haenig, Jens;
Vegni, Elena

Publication type:

Article

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib.

Published in:

Frontiers in Pharmacology, 2020, p. 1, doi. 10.3389/fphar.2020.00177

By:

Buclin, Thierry;
Thoma, Yann;
Widmer, Nicolas;
André, Pascal;
Guidi, Monia;
Csajka, Chantal;
Decosterd, Laurent A.

Publication type:

Article

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.

Published in:

Frontiers in Pharmacology, 2020, v. 10, p. 1, doi. 10.3389/fphar.2019.01672

By:

Adiwidjaja, Jeffry;
Boddy, Alan V.;
McLachlan, Andrew J.

Publication type:

Article

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.

Published in:

Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2018.03152

By:

Chang, Ming-Chin;
Cheng, Hung-I;
Hsu, Kate;
Hsu, Yen-Ning;
Kao, Chen-Wei;
Chang, Yi-Fang;
Lim, Ken-Hong;
Chen, Caleb Gonshen

Publication type:

Article

Multiple squamous cell carcinomas following introduction of nilotinib.

Published in:

Clinical & Experimental Dermatology, 2014, v. 39, n. 7, p. 791, doi. 10.1111/ced.12388

By:

Peters, P.;
Rabbolini, D.;
Sinnya, S.;
Khosrotehrani, K.;
Wagner, G.

Publication type:

Article

Imatinib-Induced Hypogammaglobulinemia in Children and Adolescents with Chronic Myeloid Leukemia.

Published in:

2020

By:

Totadri, Sidharth;
Thipparapu, Shankar;
Aggarwal, Ritu;
Sharma, Madhulika;
Naseem, Shano;
Jain, Richa;
Trehan, Amita;
Malhotra, Pankaj;
Varma, Neelam;
Bansal, Deepak

Publication type:

Report

Nilotinib-Induced Keratosis Pilaris.

Published in:

2016

By:

Leong, Wai Mun Sean;
Aw, Chen Wee Derrick

Publication type:

Case Study

Identification and Targeting of Thomsen–Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 609, doi. 10.2147/OTT.S255299

By:

Eldesouki, Raghda E;
Wu, Chengxiang;
Saleh, Fayez M;
Mohammed, Eman Abdel-Moemen;
Younes, Soha;
Hassan, Naglaa Elsayed;
Brown, Theresa C;
Alt, Eckhard U;
Robinson, James E;
Badr, Fouad Mohamed;
Braun, Stephen E

Publication type:

Article

Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 2925, doi. 10.2147/OTT.S222734

By:

Zhang, Rong;
Huo, Cai-hong

Publication type:

Article

Inhibition of KPNB1 Inhibits Proliferation and Promotes Apoptosis of Chronic Myeloid Leukemia Cells Through Regulation of E2F1.

Published in:

OncoTargets & Therapy, 2019, v. 12, p. 10455, doi. 10.2147/OTT.S210048

By:

Wang, Teng;
Huang, Zhenglan;
Huang, Ningshu;
Peng, Yuhang;
Gao, Miao;
Wang, Xin;
Feng, Wenli

Publication type:

Article

Tumor necrosis factor α knockout impaired tumorigenesis in chronic myeloid leukemia cells partly by metabolism modification and miRNA regulation.

Published in:

OncoTargets & Therapy, 2019, v. 12, p. 2355, doi. 10.2147/OTT.S197535

By:

Shen, Na;
Liu, Songya;
Cui, Jieke;
Li, Qing;
You, Yong;
Zhong, Zhaodong;
Cheng, Fanjun;
Guo, An-Yuan;
Zou, Ping;
Yuan, Guolin;
Zhu, Xiaojian

Publication type:

Article

TGFB 2 RS79375991 GENE POLYMORPHISM IN IRAQI CHRONIC MYELOID LEUKEMIA PATIENTS INFECTIOUS WITH HUMAN HERPES VIRUS-8.

Published in:

Obstetrics & Gynaecology Forum, 2024, v. 34, n. 3, p. 1764

By:

Issa, Narjis Ehsan;
Al. Alwany, Shakir H. Mohammed

Publication type:

Article

The importance of personalized medicine in chronic myeloid leukemia management: a narrative review.

Published in:

Egyptian Journal of Medical Human Genetics, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s43042-023-00411-3

By:

Zaker, Erfan;
Nouri, Negar;
Sorkhizadeh, Sepehr;
Ghasemirad, Hamidreza;
Hajijafari, Amir Hossein;
Zare, Fateme

Publication type:

Article

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

Published in:

Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01642-6

By:

Hughes, Timothy P.;
Saglio, Giuseppe;
Geissler, Jan;
Kim, Dong-Wook;
Lomaia, Elza;
Mayer, Jiri;
Turkina, Anna;
Kapoor, Shruti;
Cardoso, Ana Paula;
Nieman, Becki;
Quenet, Sara;
Cortes, Jorge E.

Publication type:

Article

Response rate of imatinib among patients with chronic myeloid leukemia in Thailand: A retrospective study.

Published in:

Thai Journal of Pharmaceutical Sciences, 2024, v. 48, n. 1, p. 1

By:

Yodsurang, Natthawat;
Niamhun, Narawadee;
Rattanathammethee, Thanawat;
Sirichanchuen, Buntitabhon

Publication type:

Article

Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia.

Published in:

PLoS ONE, 2019, v. 14, n. 3, p. 1, doi. 10.1371/journal.pone.0213557

By:

Mulu Fentie, Atalay;
Tadesse, Fishatsion;
Engidawork, Ephrem;
Gebremedhin, Am

Publication type:

Article

Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Published in:: 2018
Publication type:: Correction Notice

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

Published in:

PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0192180

By:

Eadie, Laura N.;
Dang, Phuong;
Goyne, Jarrad M.;
Hughes, Timothy P.;
White, Deborah L.

Publication type:

Article

Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation.

Published in:

Journal of Clinical Pharmacology, 2024, v. 64, n. 3, p. 323, doi. 10.1002/jcph.2379

By:

Liu, Xiaomei I.;
Leong, Ruby;
Burckart, Gilbert J.;
Dallmann, André

Publication type:

Article

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.

Published in:

Journal of Clinical Pharmacology, 2018, v. 58, n. 12, p. 1533, doi. 10.1002/jcph.1312

By:

Tian, Xianbin;
Zhang, Hefei;
Heimbach, Tycho;
He, Handan;
Buchbinder, Aby;
Aghoghovbia, Mary;
Hourcade‐Potelleret, Florence

Publication type:

Article

Exploring the pharmacokinetics of second-generation cephalosporin, cefaclor: a systematic review in healthy and diseased populations.

Published in:

Xenobiotica, 2024, v. 54, n. 4, p. 171, doi. 10.1080/00498254.2024.2333009

By:

Saleem, Tahir;
Zamir, Ammara;
Rasool, Muhammad Fawad;
Imran, Imran;
Saeed, Hamid;
Alqahtani, Faleh

Publication type:

Article

Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1.

Published in:

Xenobiotica, 2018, v. 48, n. 10, p. 1059, doi. 10.1080/00498254.2017.1393582

By:

Koide, Hiroyoshi;
Tsujimoto, Masayuki;
Takeuchi, Ai;
Tanaka, Miyu;
Ikegami, Yoko;
Tagami, Mayu;
Abe, Syoko;
Hashimoto, Miki;
Minegaki, Tetsuya;
Nishiguchi, Kohshi

Publication type:

Article

Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors.

Published in:

Nature Medicine, 2015, v. 21, n. 7, p. 786, doi. 10.1038/nm.3869

By:

Lemos, Dario R;
Babaeijandaghi, Farshad;
Low, Marcela;
Chang, Chih-Kai;
Lee, Sunny T;
Fiore, Daniela;
Zhang, Regan-Heng;
Natarajan, Anuradha;
Nedospasov, Sergei A;
Rossi, Fabio M V

Publication type:

Article